CREDENCE: A New Perspective Specialist Care | Diabetes on the Net

Diabetes on the Net is intended for healthcare professionals

This promotional webcast has been developed by Napp Pharmaceuticals Limited and Napp products will be discussed. Napp has fully funded the meeting and is responsible for the content, logistics and selection of speakers. OmniaMed has provided editorial, marketing and logistical support.

specialist care

CREDENCE:
Type 2 Diabetes Management
- A New Perspective

Protect the kidney to protect the heart

Join us for our upcoming online webcast taking place on
21 July 2020 at 12.30 and 19.00

Taking place online

What does the CREDENCE trial mean for the management of diabetic kidney disease (DKD) in type 2 diabetes mellitus (T2DM) for specialists?

In this promotional webcast, aimed specifically at renal, diabetes and cardiology specialists, we will take an exclusive look at the CREDENCE trial and assesses how Invokana® (canagliflozin) may change the management of DKD in T2DM in the secondary care setting.

By attending, you will gain unique insight into:

  • The CREDENCE trial design and results from two of the lead investigators
  • How the findings of CREDENCE translate into the specialist setting.

This 80-minute broadcast includes a 20-minute live Q&A, where you will be able to put your questions to the speakers; it will be broadcast twice, at 12.30 and 19.00 on 21 July 2020.

Join us for our upcoming online webcast

Taking place on 21 July 2020

12.30 and 19.00

Your Speakers

Professor Vlado Perkovic

Dean of Medicine at UNSW Sydney, and Specialist in Nephrology at the Royal North Shore Hospital

Professor Vlado Perkovic is Dean of Medicine at University of New South Wales, Sydney, and a Staff Specialist in Nephrology at the Royal North Shore Hospital. His research focus is in clinical trials and epidemiology, in particular preventing the progression of kidney disease and its complications.

He leads several international clinical trials, and has been involved in developing Australian and global treatment guidelines. He has played a central role in the development of an affordable dialysis system, which was a Eureka Prize finalist in 2017.

Vlado is a member of the National Health and Medical Research Council Principal Committee on Research Translation, and is on the Board of the Australian Clinical Trials Alliance and the Association of Australian Medical Research Institutes. He is Chair of the International Society of Nephrology Advancing Clinical Trials (ISN-ACT) group, and is a Fellow of the Royal Australasian College of Physicians and the Australian Academy of Health and Medical Sciences. He serves on the editorial boards of a number of leading specialist and general journals, including the Journal of the American Society of Nephrology, Circulation, and the New England Journal of Medicine.

Dr Iain Cranston

Consultant Physician [Diabetes, Endocrinology] at Portsmouth Hospitals NHS Trust

Dr Iain Cranston is a diabetes physician based in Portsmouth, UK. He has specialty responsibility for the delivery of technology-driven services (continuous subcutaneous insulin infusion, continuous glucose monitoring, etc.) to approximately 1% of the UK population. Alongside this, he is the lead diabetes clinician for the Wessex renal and transplant centre, managing individuals with specific and high glycaemic risks. He is a national committee member for the Diabetes Technology Network.

He has a background in clinical research – obtained during his time at Guy’s, King’s College and St Thomas’ Hospitals – into impaired awareness of hypoglycaemia in insulin-treated diabetes, and the cerebral and endocrine mechanisms underlying the syndrome. For the last 20 years, Dr Cranston has been in practice with the goal of translating the lessons learnt from research into routine clinical care consultations. This has resulted in a focus on effective glucose monitoring strategies to underpin clinical decision-making, and the development of data analytical processes to guide clinical consultations towards more effective therapeutic interventions in both type 1 and type 2 diabetes. He has published over 60 peer-reviewed publications in this area and has been an invited speaker at many national and international meetings.

For the last 5 years, Dr Cranston has been a co-director in a collaborative educational project with Professor Roger Mazze (International Diabetes Center, Minnesota) at the AGP Clinical Academy, which has the goal of educating healthcare professionals in the effective clinical interpretation of the ambulatory glucose profile derived from continuous glucose monitoring technologies.

Dr Robert Lewis

Consultant Renal Physician at Portsmouth Hospitals NHS Trust

Dr Robert Lewis has been a consultant nephrologist at the Wessex Kidney Centre (WKC) since 1997. The department provides nephrology, dialysis and transplantation services to an extensive area of the central south coast of England. Dr Lewis’s own clinical practice is in West Sussex.

He graduated from the Westminster Medical School (now Imperial College London) in 1984 and undertook his renal training at St Bartholomew’s Hospital, King’s College Hospital and Guy’s Hospital. He completed his thesis at Guy’s Hospital in 1996 before moving to the south coast.

He was a founder member of the Chronic Kidney Disease (CKD) Strategy Committee for the British Renal Society and was a member of the development group for the 2014 National Institute for Health and Care (NICE) guidelines for management of CKD in adults. He authored and edited an online teaching resource (CKD Online) in 2010 and published a textbook on CKD in 2012. He was a member of the NICE quality standards advisory committee for CKD in 2016-17.

He has twice been Head of Department of the WKC but is now focusing on research. He is currently Head of Research and Innovation at WKC, Senior Lecturer at the University of Portsmouth and Renal Specialty Lead for the Wessex Clinical Research Network.

Professor David Wheeler

Honorary Consultant Nephrologist, Professor of Kidney Medicine, Royal Free, London

Professor David Wheeler’s current positions include Professor of Kidney Medicine at University College London, Honorary Consultant Nephrologist at the Royal Free London NHS Foundation Trust and Honorary Professorial Fellow of the George Institute for Global Health, Sydney, Australia. He is a Clinician Scientist with an interest in the complications of chronic kidney disease, specifically those that increase the burden of cardiovascular disease and/or accelerate progression of kidney failure. He has contributed to the development and running of several large-scale clinical trials involving patients with chronic kidney disease including SHARP, EVOLVE and CREDENCE. He is currently co-chief investigator of the DAPA-CKD study.

Locally, Professor Wheeler heads the clinical research team at the Centre for Nephrology, Royal Free Hospital in London. He has been involved in Clinical Practice Guideline Development for several organisations, most recently for Kidney Disease: Improving Global Outcomes (KDIGO), of which he is currently co-chair. He has served terms as President of the UK Renal Association, Chair of the UK Renal Registry and Associate Editor of Nephrology Dialysis Transplantation (NDT).

Agenda

21 July 2020

Session 1 (20 mins)

Chair's introduction
The CREDENCE study and the current management of DKD in type 2 diabetes

  • Why was the CREDENCE study done?
  • Chair’s introduction
  • CREDENCE study background and design
  • What are the current unmet needs in the specialist setting?

Prof David Wheeler

Session 2 (20 mins)

CREDENCE: bringing the data to life

  • CREDENCE: detailed study results
  • What does this data add?
  • What does this mean in practice?

Prof Vlado Perkovic

Session 3 (20 mins)

How does the CREDENCE
data translate in a specialist setting?
An expert discussion

  • How might this change our current practice?
  • Does this pave the way for closer collaboration between the diabetes and renal teams?
  • What should we be looking out for in patient outcomes?
  • Dosing considerations

Dr Iain Cranston and Dr Robert Lewis

Session 4 (20 mins)

Live Q&A

Moderated by the Chair

Book your place on our upcoming webcast

What does the CREDENCE trial mean for the management of diabetic kidney disease in type 2 diabetes for specialists?

21 July 2020

12.30 and 19.00

Days
Hours
Min
Sec

Upcoming webcast

A promotional webcast from
Napp Pharmaceuticals Limited

Primary Care
Type 2 Diabetes Management -
A New Perspective​

Protect the kidney to protect the heart

22 July 2020

In association with

Adverse events should be reported. Reporting forms and information can be found at yellowcard.mhra.gov.uk
Adverse events should also be reported to Napp Pharmaceuticals at drugsafetyuk@napp.co.uk
Date of preparation: July 2020 UK/INv-20107j

Complete the registration form

Your data is being collected by OmniaMed Communications on behalf of Napp Pharmaceuticals Limited solely for the purpose of processing your registration. Your details will not be shared with any parties other than OmniaMed Communications and Napp.
This promotional webcast has been developed by Napp Pharmaceuticals Limited and Napp products will be discussed. Napp has fully funded the meeting and is responsible for the content, logistics and selection of speakers. OmniaMed has provided editorial, marketing and logistical support.
Date of preparation: July 2020 UK/INv-20107j

We use cookies to ensure that we give you the best experience on our website. Some may have been set already. If you continue without changing your settings, we’ll assume that you are happy to receive all cookies on this website. Read about how we use cookies. If you have any concerns about this, please click here to find out more.

See you on 21 July 2020

Days
Hours
Minutes
Seconds

Thanks for registering!

This promotional webcast has been developed by Napp Pharmaceuticals Limited and Napp products will be discussed. Napp has fully funded the meeting and is responsible for the content, logistics and selection of speakers. OmniaMed has provided editorial, marketing and logistical support.
Date of preparation July 2020 UK/INv-20107j